Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 3, 2025 • 12:31 PM ET

Date/Time Source News Release
11/12/2024 04:01 PM EST GlobeNewswire Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/15/2024 07:00 AM EDT GlobeNewswire Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
09/27/2024 07:00 AM EDT GlobeNewswire Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
08/14/2024 04:01 PM EDT GlobeNewswire Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
05/21/2024 09:14 AM EDT GlobeNewswire Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
05/06/2024 07:59 AM EDT GlobeNewswire Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
04/30/2024 04:04 PM EDT GlobeNewswire Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/26/2024 04:51 PM EDT GlobeNewswire Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/21/2024 04:01 PM EDT GlobeNewswire Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
03/01/2024 04:01 PM EST GlobeNewswire Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Page

Additional News

As of January 3, 2025 • 12:31 PM ET

Date/Time Source News Release
11/27/2024 04:31 AM EST US Earnings Reports Expected earnings - Lyra Therapeutics Inc.
11/13/2024 03:03 AM EST SeekingAlpha Lyra Therapeutics GAAP EPS of -$0.18 beats by $0.02, revenue of $0.2M misses by $0.06M
11/12/2024 05:15 PM EST Zacks Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
11/08/2024 08:10 AM EST Zacks Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates
08/15/2024 01:50 PM EDT SeekingAlpha Lyra Therapeutics still sees potential in rhinosinusitis asset despite setbacks
08/14/2024 05:30 PM EDT Zacks Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
08/12/2024 07:10 AM EDT Zacks Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
08/08/2024 08:25 AM EDT Zacks OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
05/21/2024 10:21 AM EDT SeekingAlpha Lyra to cut 75% of workforce in portfolio shakeup
05/07/2024 12:15 PM EDT KlickAnalytics Buy Recommendation Issued On LYRA By Jefferies
Page